slx-2101
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00562614)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 5AINHIBITOR
PDE5A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- slx-2101
- slx-2101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00562549 | Phase 2 | Jul 1, 2007 | Kadmon, University of Cambridge |
| NCT00528242 | Phase 2 | Jun 1, 2007 | Kadmon, Saarland University |
| NCT00562614 | Phase 2 | Jun 1, 2007 | Kadmon, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kadmon | For profit | 3 | 3 | 1 | 2007 |
| Parexel | For profit | 1 | 0 | 1 | 2007 |
| Saarland University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2007 |
4 organizations
Page 1 / 1